US 12,264,343 B2
TCRa homing endonuclease variants
Jordan Jarjour, Seattle, WA (US); and Mark Pogson, North Bend, WA (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Feb. 24, 2023, as Appl. No. 18/174,165.
Application 18/174,165 is a continuation of application No. 16/340,257, granted, now 11,591,582, previously published as PCT/US2017/056178, filed on Oct. 11, 2017.
Claims priority of provisional application 62/414,266, filed on Oct. 28, 2016.
Claims priority of provisional application 62/406,689, filed on Oct. 11, 2016.
Prior Publication US 2023/0357736 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); C12N 15/85 (2006.01)
CPC C12N 9/22 (2013.01) [C12N 15/85 (2013.01)] 19 Claims
 
1. A method of editing a genome of a cell, comprising: introducing into the cell one or more polynucleotides comprising a nucleotide sequence encoding a polypeptide comprising an I-OnuI homing endonuclease (HE) variant that cleaves a target site in the human T-cell receptor alpha (TCRα) gene, wherein the I-OnuI HE variant comprises an amino acid sequence that is at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 8.